290 related articles for article (PubMed ID: 9091644)
1. Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth.
Kawakita M; Rao GS; Ritchey JK; Ornstein DK; Hudson MA; Tartaglia J; Paoletti E; Humphrey PA; Harmon TJ; Ratliff TL
J Natl Cancer Inst; 1997 Mar; 89(6):428-36. PubMed ID: 9091644
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses.
Griffith TS; Kawakita M; Tian J; Ritchey J; Tartaglia J; Sehgal I; Thompson TC; Zhao W; Ratliff TL
J Natl Cancer Inst; 2001 Jul; 93(13):998-1007. PubMed ID: 11438565
[TBL] [Abstract][Full Text] [Related]
3. Viral vector delivery in solid-state vehicles: gene expression in a murine prostate cancer model.
Siemens DR; Austin JC; Hedican SP; Tartaglia J; Ratliff TL
J Natl Cancer Inst; 2000 Mar; 92(5):403-12. PubMed ID: 10699070
[TBL] [Abstract][Full Text] [Related]
4. [Poxvirus vectors for gene transfer].
Kawakita M; Yoshida O; Ratliff TL
Hinyokika Kiyo; 1997 Nov; 43(11):835-8. PubMed ID: 9436032
[TBL] [Abstract][Full Text] [Related]
5. Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNF-alpha combination therapy.
Grant JF; Iwasawa T; Sinn HW; Siemens DR; Griffith TS; Takacs EB; Ratliff TL
Int J Cancer; 2006 Dec; 119(11):2632-41. PubMed ID: 16991124
[TBL] [Abstract][Full Text] [Related]
6. Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity.
Puisieux I; Odin L; Poujol D; Moingeon P; Tartaglia J; Cox W; Favrot M
Hum Gene Ther; 1998 Nov; 9(17):2481-92. PubMed ID: 9853515
[TBL] [Abstract][Full Text] [Related]
7. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors.
Elzey BD; Siemens DR; Ratliff TL; Lubaroff DM
Int J Cancer; 2001 Dec; 94(6):842-9. PubMed ID: 11745487
[TBL] [Abstract][Full Text] [Related]
8. Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53.
Odin L; Favrot M; Poujol D; Michot JP; Moingeon P; Tartaglia J; Puisieux I
Cancer Gene Ther; 2001 Feb; 8(2):87-98. PubMed ID: 11263530
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma.
Triozzi PL; Allen KO; Carlisle RR; Craig M; LoBuglio AF; Conry RM
Clin Cancer Res; 2005 Jun; 11(11):4168-75. PubMed ID: 15930353
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of whole-cell tumor preparations infected with the ALVAC viral vector.
Ghose A; Iakhnina E; Spaner D; Tartaglia J; Berinstein NL
Hum Gene Ther; 2000 Jun; 11(9):1289-301. PubMed ID: 10890739
[TBL] [Abstract][Full Text] [Related]
11. ALVAC-mediated gene transfer is efficient in lymphoid malignancies of T-and early B-cell origin, but not in tumors arising from mature B-cells.
Gitelson E; Ghose A; Buckstein R; Imrie K; Lim MS; Reis M; Spaner D; Tartaglia J; Berinstein NL
Cancer Immunol Immunother; 2001 Sep; 50(7):345-55. PubMed ID: 11676394
[TBL] [Abstract][Full Text] [Related]
12. Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells.
Motta I; André F; Lim A; Tartaglia J; Cox WI; Zitvogel L; Angevin E; Kourilsky P
J Immunol; 2001 Aug; 167(3):1795-802. PubMed ID: 11466405
[TBL] [Abstract][Full Text] [Related]
13. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
[TBL] [Abstract][Full Text] [Related]
14. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.
Hodge JW; McLaughlin JP; Kantor JA; Schlom J
Vaccine; 1997; 15(6-7):759-68. PubMed ID: 9178479
[TBL] [Abstract][Full Text] [Related]
15. Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy.
Ferrari G; Berend C; Ottinger J; Dodge R; Bartlett J; Toso J; Moody D; Tartaglia J; Cox WI; Paoletti E; Weinhold KJ
Blood; 1997 Sep; 90(6):2406-16. PubMed ID: 9310492
[TBL] [Abstract][Full Text] [Related]
16. Gene transfer to liver cancer cells of B7-1 plus interleukin 12 changes immunoeffector mechanisms and suppresses helper T cell type 1 cytokine production induced by interleukin 12 alone.
Sun Y; Qian C; Peng D; Prieto J
Hum Gene Ther; 2000 Jan; 11(1):127-38. PubMed ID: 10646645
[TBL] [Abstract][Full Text] [Related]
17. Silencing the expression of Cbl-b enhances the immune activation of T lymphocytes against RM-1 prostate cancer cells in vitro.
Zhou SK; Chen WH; Shi ZD; Wang SP; Li L; Wen XF; Wang YM
J Chin Med Assoc; 2014 Dec; 77(12):630-6. PubMed ID: 25249301
[TBL] [Abstract][Full Text] [Related]
18. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response.
Ullenhag GJ; Frödin JE; Mosolits S; Kiaii S; Hassan M; Bonnet MC; Moingeon P; Mellstedt H; Rabbani H
Clin Cancer Res; 2003 Jul; 9(7):2447-56. PubMed ID: 12855617
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
20. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
Xie Y; Bai O; Zhang H; Li W; Xiang J
Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
